Table 4.
Demographic and clinical characteristics of vaccinated individuals who were eligible for inclusion in the unmatched and matched cohort studies
| mRNA-1273 (unmatched) | BNT162b2 (unmatched) | mRNA-1273 (matched) | BNT162b2 (matched) | |
|---|---|---|---|---|
| Total number of individuals | ||||
| At least one dose | 55,277 | 108,996 | 20,890 | 20,890 |
| Fully vaccinated per protocol AND matched individual also fully vaccinated per protocol | 45,534 | 92,547 | 15,392 | 15,392 |
| Age groups in years | ||||
| 18–24 | 2,987 (5.4%) | 7,352 (6.7%) | 1,119 (5.4%) | 1,119 (5.4%) |
| 25–34 | 4,675 (8.5%) | 14,516 (13.3%) | 1,839 (8.8%) | 1,839 (8.8%) |
| 35–44 | 5,777 (10.5%) | 15,608 (14.3%) | 2,205 (10.6%) | 2,205 (10.6%) |
| 45–54 | 6,789 (12.3%) | 15,701 (14.4%) | 2,618 (12.5%) | 2,618 (12.5%) |
| 55–64 | 11,077 (20.0%) | 21,782 (20.0%) | 4,583 (21.9%) | 4,583 (21.9%) |
| 65–74 | 14,939 (27.0%) | 17,912 (16.4%) | 5,939 (28.4%) | 5,939 (28.4%) |
| 75–84 | 6,650 (12.0%) | 12,458 (11.4%) | 1,911 (9.1%) | 1,911 (9.1%) |
| 85+ | 2,383 (4.3%) | 3,667 (3.4%) | 676 (3.2%) | 676 (3.2%) |
| Sex | ||||
| Female | 30,250 (54.7%) | 63,864 (58.6%) | 12,068 (57.8%) | 12,068 (57.8%) |
| Male | 25,019 (45.3%) | 45,120 (41.4%) | 8,822 (42.2%) | 8,822 (42.2%) |
| Unknown | 8 (0.0%) | 12 (0.0%) | ||
| Race | ||||
| Asian | 1,087 (2.0%) | 3,244 (3.0%) | 218 (1.0%) | 218 (1.0%) |
| Black/African American | 1,505 (2.7%) | 3,156 (2.9%) | 261 (1.2%) | 261 (1.2%) |
| Native American | 204 (0.4%) | 304 (0.3%) | 2 (0.0%) | 2 (0.0%) |
| Native Hawaiian/Pacific Islander | 49 (0.1%) | 104 (0.1%) | ||
| White | 50,527 (91.4%) | 98,008 (89.9%) | 20,208 (96.7%) | 20,208 (96.7%) |
| Other | 1,121 (2.0%) | 2,570 (2.4%) | 101 (0.5%) | 101 (0.5%) |
| Unknown | 784 (1.4%) | 1,610 (1.5%) | 100 (0.5%) | 100 (0.5%) |
| Ethnicity | ||||
| Hispanic or Latino | 2,143 (3.9%) | 4,037 (3.7%) | 207 (1.0%) | 207 (1.0%) |
| Not Hispanic or Latino | 51,672 (93.5%) | 102,021 (93.6%) | 20,535 (98.3%) | 20,535 (98.3%) |
| Unknown | 1,462 (2.6%) | 2,938 (2.7%) | 148 (0.7%) | 148 (0.7%) |
| Number of PCR tests taken prior to day of first vaccination | ||||
| 0 | 0 (0.0%) | 0 (0.0%) | ||
| 1 | 29,368 (53.1%) | 55,413 (50.8%) | 11,180 (53.5%) | 11,180 (53.5%) |
| 2+ | 25,909 (46.9%) | 53,583 (49.2%) | 9,710 (46.5%) | 9,710 (46.5%) |
| Elixhauser Comorbidity Score | ||||
| 0 | 37,708 (68.2%) | 79,024 (72.5%) | 15,751 (75.4%) | 15,751 (75.4%) |
| 1–4 | 7,977 (14.4%) | 14,863 (13.6%) | 2,544 (12.2%) | 2,544 (12.2%) |
| 5–9 | 6,528 (11.8%) | 10,511 (9.6%) | 1,894 (9.1%) | 1,894 (9.1%) |
| 10+ | 3,064 (5.5%) | 4,598 (4.2%) | 701 (3.4%) | 701 (3.4%) |
| First dose vaccine site | ||||
| Arizona | 2,351 (4.3%) | 4,326 (4.0%) | 1,114 (5.3%) | 1,114 (5.3%) |
| Florida | 7,538 (13.6%) | 8,861 (8.1%) | 1,786 (8.5%) | 1,786 (8.5%) |
| Mayo Clinic Health System | 11,584 (21.0%) | 37,290 (34.2%) | 5,644 (27.0%) | 5,644 (27.0%) |
| Rochester (Minnesota) | 6,009 (10.9%) | 26,614 (24.4%) | 3,714 (17.8%) | 3,714 (17.8%) |
| Other/not recorded | 27,795 (50.3%) | 31,905 (29.3%) | 8,632 (41.3%) | 8,632 (41.3%) |
| State of primary residence | ||||
| Arizona | 4,722 (8.5%) | 10,746 (9.9%) | 2,734 (13.1%) | 2,734 (13.1%) |
| Florida | 9,228 (16.7%) | 10,818 (9.9%) | 2,262 (10.8%) | 2,262 (10.8%) |
| Iowa | 1,385 (2.5%) | 1,373 (1.3%) | 127 (0.6%) | 127 (0.6%) |
| Minnesota | 29,110 (52.7%) | 59,529 (54.6%) | 12,067 (57.8%) | 12,067 (57.8%) |
| Wisconsin | 8,288 (15.0%) | 22,695 (20.8%) | 3,595 (17.2%) | 3,595 (17.2%) |
| Other | 2,544 (4.6%) | 3,835 (3.5%) | 109 (0.5%) | 109 (0.5%) |
| Follow-up days since first dose | ||||
| Minimum | 0 | 0 | 1 | 5 |
| 25th percentile | 180 | 169 | 174 | 181 |
| Median | 207 | 201 | 197 | 203 |
| 75th percentile | 230 | 237 | 217 | 224 |
| Maximum | 293 | 294 | 278 | 288 |
Characteristics correspond to the set of individuals who received at least one dose in each group. To be considered as fully vaccinated per protocol, an individual had to receive two vaccine doses on schedule (25–35 days apart for mRNA-1273 and 18–28 days apart for BNT162b2) and be at risk for infection as of their date of full vaccination (14 days after the second dose). For the matched analysis, only the matched pairs in which both individuals were fully vaccinated per protocol were considered.